Elite Pharmaceuticals (ELTP) Short Interest Ratio & Short Volume

Short interest is the volume of Elite Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 2,317,200 shares of ELTP short. 0.25% of Elite Pharmaceuticals' shares are currently sold short. Learn More on Elite Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ELTP shares currently have a short interest ratio of 1.0. Learn More on Elite Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.25% of Elite Pharmaceuticals' floating shares are currently sold short.

Elite Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,317,200 shares, an increase of 1.0% from the previous total of 2,293,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.25% of Elite Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Elite Pharmaceuticals: MoonLake Immunotherapeutics (11.56%), Viking Therapeutics, Inc. (26.43%), Kymera Therapeutics, Inc. (13.86%), Alvotech (1.28%), Immunovant, Inc. (29.05%), Crinetics Pharmaceuticals, Inc. (11.55%), Catalyst Pharmaceuticals, Inc. (7.07%), HUTCHMED (China) Limited Sponsored ADR (0.26%), Amneal Pharmaceuticals, Inc. (3.72%), Mirum Pharmaceuticals, Inc. (14.66%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks.

Short selling ELTP is an investing strategy that aims to generate trading profit from Elite Pharmaceuticals as its price is falling. ELTP shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Elite Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ELTP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ELTP, twice per month. The most recent reporting period available is June, 15 2025.